These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 23744519)

  • 1. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
    Ziganshina LE; Titarenko AF; Davies GR
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD004795. PubMed ID: 23744519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroquinolones for treating tuberculosis.
    Ziganshina LE; Squire SB
    Cochrane Database Syst Rev; 2008 Jan; (1):CD004795. PubMed ID: 18254061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolones for treating tuberculosis.
    Ziganshina LE; Vizel AA; Squire SB
    Cochrane Database Syst Rev; 2005 Jul; (3):CD004795. PubMed ID: 16034951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month therapy for abdominal tuberculosis.
    Jullien S; Jain S; Ryan H; Ahuja V
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis.
    Gallardo CR; Rigau Comas D; Valderrama Rodríguez A; Roqué i Figuls M; Parker LA; Caylà J; Bonfill Cosp X
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD009913. PubMed ID: 27186634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid for drug-resistant pulmonary tuberculosis.
    Singh B; Cocker D; Ryan H; Sloan DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolones for the treatment of pulmonary tuberculosis.
    Moadebi S; Harder CK; Fitzgerald MJ; Elwood KR; Marra F
    Drugs; 2007; 67(14):2077-99. PubMed ID: 17883288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent versus daily therapy for treating tuberculosis in children.
    Bose A; Kalita S; Rose W; Tharyan P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD007953. PubMed ID: 24470141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis.
    Li D; Wang T; Shen S; Cheng S; Yu J; Zhang Y; Zhang C; Tang H
    PLoS One; 2015; 10(12):e0145066. PubMed ID: 26669635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
    Kuehn R; Stoesser N; Eyre D; Darton TC; Basnyat B; Parry CM
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD010452. PubMed ID: 36420914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
    Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).
    Yotsu RR; Richardson M; Ishii N
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012118. PubMed ID: 30136733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.
    Theron G; Peter J; Richardson M; Barnard M; Donegan S; Warren R; Steingart KR; Dheda K
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010705. PubMed ID: 25353401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
    Jawahar MS; Banurekha VV; Paramasivan CN; Rahman F; Ramachandran R; Venkatesan P; Balasubramanian R; Selvakumar N; Ponnuraja C; Iliayas AS; Gangadevi NP; Raman B; Baskaran D; Kumar SR; Kumar MM; Mohan V; Ganapathy S; Kumar V; Shanmugam G; Charles N; Sakthivel MR; Jagannath K; Chandrasekar C; Parthasarathy RT; Narayanan PR
    PLoS One; 2013; 8(7):e67030. PubMed ID: 23843980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.